Top news of the day from across the health care landscape.
Drug manufacturers will be required to share the list prices of their prescription medications in TV ads, The Associated Press reported. According to the article, Health and Human Services Secretary Alex Azar told The Associated Press that the administration is finalizing regulations that will require drug companies to disclose list prices for medications costing more than $35 for a month’s supply. The pricing details are expected to appear in text toward the end of commercials when potential adverse effects are disclosed, the article reported.
An investigational breast cancer drug demonstrated a clinically meaningful response in patients in a mid-stage study, Reuters reported. According to the article, trastuzumab deruxtecan, also known as DS-8201, was evaluated in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who could no longer be helped with Roche’s Kadcyla. There are currently 5 DS-8201 late-stage patient trials underway that may be used in requests for marketing approval, the article reported.
A new survey found that pharmacy students had a high awareness of pre-exposure prophylaxis (PrEP) and generally positive attitudes toward it, The American Journal of Managed Care reported. According to the article, 91% of the 291 students who were surveyed were aware of PrEP and 61% reported high familiarity with PrEP prescription guidelines. However, 55% of participants knew the daily dosing frequency and approved medication for PrEP and just 44.2% knew that HIV testing was required before prescribing the prevention pill, the article reported.